The influence of tobacco smoking on adhesion molecule profiles by Scott, DA & Palmer, RM





1Department of Oral Biology, University of Manitoba, Canada
2Department of Periodontology and Preventive Dentistry, Kings College London, UK
Abstract.Sequential interactions between several adhesion molecules and their ligands regulate lym-
phocyte circulation and leukocyte recruitment to inflammatory foci. Adhesion molecules are, therefore,
central and critical components of the immune and inflammatory system. We review the evidence that
tobaccosmokingdysregulatesspecificcomponentsoftheadhesioncascade,whichmaybeacommonfac-
tor in several smoking-induced diseases. Smoking causes inappropriate leukocyte activation, leukocy-
te-endothelialadhesion,andneutrophilentrapmentinthemicrovasculature,whichmayhelpinitiatelocal
tissue destruction. Appropriate inflammatory reactions may thus be compromised. In addition to smo-
ke-induced alterations to membrane bound endothelial and leukocyte adhesion molecule expression,
whichmayhelpexplaintheabovephenomena,smokinghasaprofoundinfluenceoncirculatingadhesion
molecule profiles, most notably sICAM-1 and specific sCD44 variants. Elevated concentrations of solu-
bleadhesionmoleculesmaysimplyreflectongoinginflammatoryprocesses.However,increasingeviden-
ce suggests that specific soluble adhesion molecules are immunomodulatory, and that alterations to
soluble adhesion molecule profiles may represent a significant risk factor for several diverse diseases.
This evidence is discussed herein.
Key words: adhesion molecules; cancer; CD44; chronic obstructive lung disease; ICAM-1; periodonti-
tis; selectins; smoking; tobacco; vascular disease.
INTRODUCTION
Smoking leads to a generalised leukocytosis [1-7]; influences
the production of most immunoglobulin classes and
sub-classes [8-11]; can induce T cell anergy (failure to re-
spond to antigen)[12-14]; effect vascular dynamics [15-19];
cause inappropriate priming and activation of monocytes and
neutrophils [4, 20, 21]; abnormal platelet aggregation [22,
23]; and a generalized increase in local and systemic inflam-
matory markers [21, 24, 25]. Therefore, there is considerable
evidencethatsmokingexertsprofoundinfluencesonmultiple
components of the immune and inflammatory system in
humans, various aspects of which have been ably reviewed
elsewhere [4, 14, 16, 26, 27]. This paper will focus on the in-
fluence of tobacco smoking on a group of molecules that func-
tion at the heart of the immune and inflammatory response -
the cellular adhesion molecules.
ADHESION MOLECULE OVERVIEW
Adhesion molecules share the common physiological role of
promoting cell-cell or cell-extracellular matrix adhesion, and
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The ability of lymphocytes (B cells and T cells) to circulate be-
tween the blood and secondary lymphoid tissue, and the move-
ment of leukocytes (lymphocytes and other white blood cells,
such as neutrophils and monocytes) from the systemic circula-
tiontolocalsitesofinflammation,aremajorandcriticalcompo-
nents of the immune response. Leukocytes must, therefore,
interact with and cross endothelial barriers  either the high en-
dothelial venules of the lymphatic system or the endothelial
cells forming the microvasculature. The sequential processes
of capture, rolling and adhesion of leukocytes to endothelial
cells, and subsequent leukocyte extravasation and migration to
specific sites, are mediated and controlled by a complex and
overlapping series of interactions between adhesion molecules
andtheirspecificligands-anadhesioncascade-asrepresented
in Figure 1 [28-31].
Essentially, leukocyte capture is mediated by P-selectin
(CD62P) and L-selectin (CD62L). Rolling is mediated by
P-selectin, L-selectin, and a third member of the selectin fam-
ily of adhesion molecules, E-selectin (CD62E). Firm adhe-
sion is mediated by interactions between intercellular
adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhe-
sion molecule-1 (VCAM-1; CD106) and their ligands - the b2
integrins(particularyLFA-1[aLb2;CD11a/CD18]andMac-1
[aMb2; CD11b/CD18]) and very late-antigen-4 (VLA-4;
CD49d), respectively - following further activation of the
adhesion cascade by locally produced chemokines, and/or
other stimuli, such as RANTES, fractaline, and stromal
cell-derived factor-1a (SDF-1a) and SDF-1b, as reviewed in
[31]. Extravasation through endothelial-endothelial cell junc-
tions is less well understood. However, homophilic interac-
tions of specific adhesion molecules [junctional adhesion
molecules (JAM), platelet-endothelial cell adhesion mole-
cule-1 (PECAM-1; CD31), and vascular endothelial cadherin
(VE-cadherin; CDH5)] may play important roles in maintain-
ing endothelial-endothelial cell adhesion, and these adhesion
molecule interactions are probably disrupted in order to per-
mit leukocyte transmigration [31-34]. Although the impor-
tance of another adhesion molecule, CD44, in lymphocyte
homing has been known for some time, there is increasing evi-
dence to suggest that CD44 is also involved in leukocyte adhe-
sion and transmigration processes during inflammation
[30, 35]. Glycosylation, and other post-translational modi-
fications; expression densities of adhesion molecules, and
their ligands, on leukocytes and endothelial cells; activa-
tion-induced alterations in the affinity of adhesion molecules
for specific ligands; intracellular signal transduction path-
ways initiated on rolling; and co-operation between various
adhesion molecules, all influence leukocyte/endothelial inter-
actions, as reviewed elsewhere [28, 31, 36-42]. Significant
interferencewithleukocytetransmigrationduetoenvironmen-
tal, acquired, or genetic factor(s) may be expected to have pro-
foundconsequences.Aclassicexampleisleukocyteadhesion
deficiency type I, a rare genetic disorder defined by insuffi-
cient or non-functional CD18, the common chain of the
b2-integrins, resulting in compromised leukocyte trafficking,
reflected in severe and recurrent bacterial infections, and de-
layed wound healing. This paper will focus on the evidence
that tobacco smoking also influences the expression and re-
lease of specific adhesion molecules.
ICAM-1 and CD44
Of the major adhesion molecules, the evidence presented
below will necessitate a particular focus on two  ICAM-1
and CD44. ICAM-1 is an integral membrane glycoprotein
with five extracellular immunoglobulin-like domains and a
shortcytoplasmictail,encodedbya3.3kbmRNAtranscribed
from a single gene with no alternate exons [43, 44]. ICAM-1
is expressed constitutively by a wide variety of cell types, in-
cluding endothelial cells. Basal expression of ICAM-1 on en-
dothelial cells, and some leukocytes, can be augmented
followinginductionbyTNF-a,IL-1b,andIFN-g,andotherin-
flammatory mediators [38, 45-49]. Recognised ligands of
ICAM-1 include the b2integrins of leukocytes, hyaluronate,
sialophorin (CD43) and fibrinogen [50, 51], reflecting the ma-
jor role played by ICAM-1 immune and inflammatory
regulation.
By way of introduction to a complex adhesion molecule
family, human CD44 is a widely expressed family of
glycoproteins, encoded by a single gene containing 20 exons.
Numerous CD44 isoforms are generated through alternate
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Figure 1. Leukocyte adhesion and extravasation.
This figure has been adapted from references [28  31].
Abbreviations used: CIPD  chronic inflammatory periodontal disease;
COPD  chronic obstructive pulmonary disease; GCF - gingival
crevicular fluid; HUVEC  human umbilical vein endothelial cells;
ICAM-1-intercellularadhesionmolecule-1(CD54);LFA-1-lymphocyte
functional antigen-1 (CD11a/CD18; (aLb2); Mac-1 - CD11b/CD18
(aMb2); PECAM-1 - platelet-endothelial cell adhesion molecule-1;
VCAM-1 - vascular cell adhesion molecule-1 (CD106).splicingofpre-mRNA.However,allCD44isoformssharethe
same N- and C-terminal sequences. The haematopoetic, or
standardform,ofCD44(CD44H;CD44s)isa248aminoacid
protein that contains no variant exon-encoded peptide se-
quences. Thus CD44H is the smallest CD44 isoform, with a
molecular mass of 80-95 kDa, more than half of which is due
to post-translational glycosylation events. Splice variation
and significant post-translational modifications result in a
multifunctional group of CD44 adhesion molecules, with im-
portant functions in embryogenesis, lymphocyte activation
and homing, angiogenesis, leukocyte extravasation,
anti-apoptosis signalling, presentation of growth factors and
proteases, and cell migration and proliferation, including dur-
ing tumor metastasis [30, 52-60]. Many of these activities ap-
pear to be mediated by interaction between the extracellular
matrix component hyalouronate and CD44. However, several
other CD44 ligands are recognised, including laminin, colla-
gen, fibronectin, serglycin, osteopontin and aggrecan [57, 61,
62]. Many recent reviews address the structure, regulation,
function, clinical significance, and therapeutic targeting of
ICAM-1 [38, 50, 51, 63-67] and CD44 [30, 61-63, 68-74].




duce leukocyteendothelial adhesion, microvascular and
macrovascularentrapmentofleukocytes,andleukocyteaggre-
gation in humans and animal models [75-89]. Leukocyte-en-
dothelial binding, and subsequent leukocyte-mediated tissue
damage, is a central component of various smoking-associ-
ated inflammatory diseases, leading several groups to investi-
gate the influence of tobacco use on adhesion molecule
networks. This review will pay particular attention tochronic
obstructive pulmonary disease (COPD), direct cigarette
smoke exposure being most intense in the lungs; vascular dis-
eases, vascular endothelial cells and circulating leukocytes
being chronically exposed to systemically distributed compo-
nents and metabolites of smoke; and chronic inflammatory
periodontal disease (CIPD), with the periodontal tissues be-
ing both chronically exposed to systemic smoke components,
and transiently exposed topically.
Chronic Obstructive Pulmonary Disease
COPD is characterised by chronic coughing, obstruction
of the peripheral airways, and destruction of lung surfaces
(emphysema).AlthoughnotallsmokersdevelopCOPD,90%
of those who do develop COPD are smokers. As much of the
pulmonary tissue destruction in COPD is thought to be due to
the recruitment and activation of inflammatory cells, several
researchers have examined the influence of smoking on
adhesion molecule expression and release by the endothelial
cells comprising the pulmonary vasculature, and recruited al-
veolar inflammatory cells. Tobacco smoking results in a
significantlyincreasednumberofimmatureneutrophilsinthe
systemic circulation, characteristic of chronic stimulation of
bone marrow [7]. Accordingly, there is a small, but signifi-
cant, increase in circulating neutrophil L-selectin expression
in smokers [7]. Immature neutrophils are preferentially se-
questered in the lung microvasculature [90], and pulmonary
neutrophil entrapment is a recognised phenomenon in smok-
ers [85]. Additionally, absolute neutrophil and macrophage
numbers are increased in the alveolar space of smokers [24,
88, 91-93]. These observations point to a smoking-induced
dysregulation of adhesion molecule networks in the pulmo-
nary environment.
In support of this, Schaberg et al. [88] noted that a signifi-
cantly higher proportion of alveolar macrophages from smok-
ers expressed b2-integrin subunits than alveolar macrophages
obtained by pulmonary lavage from non-smokers. The in-
crease in b2-integrin expression correlated with increased
numbers of macrophages in the pulmonary environment. In-
creased binding of alveolar macrophages from smokers to
TNF-a stimulated human umbilical vein endothelial cells
(HUVECs) was mitigated by either pre-treatment of the endo-
thelial cells with antibodies to ICAM-1, or pre-treating alveo-
lar macrophages with antibodies to CD18. Therefore,
smoking may contribute to increased ICAM-1/b2-integrin-de-
pendent recruitment of inflammatory cells to the lungs.
Lensmar et al. [94] reported that while the sputum of smokers
(n = 9) contained more macrophages than the sputum of
non-smokers (n = 7), the percentage of macrophages express-
ing ICAM-1 was significantly lower in smokers. However,
upregulation of endothelial ICAM-1 expression is likely to be
a more important limiting factor in terms of leukocyte
recruitment.
Instudiesofthepulmonaryendothelium,thereissomeevi-
dence that ICAM-1 expression by bronchial vessels may not
be affected by smoking [95]. However, Schaberg et al. [93]
went on to observe a large increase in ICAM-1, but not
P-selectin,E-selectin,orVCAM-1,expressionbytheendothe-
lium of peripheral pulmonary vessels in smokers, compared
to non-smokers. Schaberg et al. [93] also noted a strong corre-
lation between cumulative tobacco smoke exposure
(pack-years) and the percentage of ICAM-1-positive pulmo-
nary vessels, consistent with a role for smoking in increased
pulmonary recruitment of leukocytes through the dysregu-
lation of adhesion molecule networks.
AsonlysomesmokersdevelopCOPD,thereisanobvious
interest in defining the characteristics of smokers at enhanced
risk of developing the disease [96]. To this end, Maestrelli et
al. [97] reported that the numbers of neutrophils expressing
CD11b and CD18, but not CD11a or CD11c, were increased
in smoking subjects (n = 33) with airway obstruction, com-
pared to smokers without airway obstruction, and hypothes-
isedthatCD11b/CD18expressionbysputumneutrophilsmay
represent a marker for the development of chronic airway ob-
struction among smokers. Noguera et al. [98] investigated the
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COPD and in smokers and non-smokers without COPD.
None of the COPD subjects were current smokers, although
they had a total cumulative tobacco exposure similar to the
smoking group (50 pack-years). There were no significant dif-
ferencesinMac-1,LFA-1,orL-selectinexpressionbyTNF-a
stimulated or unstimulated neutrophils isolated from smokers
or non-smokers with normal forced-expiratory volume. How-
ever, expression of Mac-1 on neutrophils was increased in
those with COPD, compared to either healthy group (smokers
or non-smokers), augmented by an increased respiratory
burst, leading the authors to suggest that neutrophil dysfunc-
tion in COPD subjects may not be directly caused by smok-
ing, but, rather, may represent a characteristic of COPD. It is
also possible that smoking may not affect all smokers equally,
and that a differential effect on CD18/CD11b expression
could discriminate smokers at increased risk of developing
COPD. However, a recent comparison of adhesion molecule
expression profiles on leukocyte (L-selectin, VLA-4, and the
three b2-integrin heterodimers), endothelial and epithelial
(E-selectin,P-selectin,VCAM-1,ICAM-1,andICAM-2)cell
surfaces in freshly resected lungs from smokers with airways
obstruction (n = 10) and smokers with normal lung function
(n = 10) revealed no significant differences in adhesion mole-
cule profiles between diseased and healthy groups [99]. The
authors, therefore, concluded that development of airways ob-
struction in smokers could not be explained by differences in
theexpressionofadhesionmoleculesknowntobeinvolvedin
the control of cell traffic in the lung.
Otherinvestigationshavemonitoredtheeffectofsmoking
on bronchial epithelial cells. Small-airway epithelial cells har-
vested from smokers exhibited significantly elevated
ICAM-1 mRNA levels, compared to non-smokers [100]. Cor-
respondingly,adramaticincreaseinICAM-1releasefromthe
surface of cultured small-airway epithelial cells of smokers






in epithelial cells isolated from the main bronchi of smokers
andnon-smokers.Similarly,diStefanoetal.[95]foundnodif-
ference in ICAM-1 expression on the bronchial epithelium of
smokersandnon-smokers.Cigarettesmokeexposureresulted
in a significant increase (up to 175%) in sICAM-1 release
from primary explant cultures of human bronchial epithelial
cells obtained from never-smokers, or smokers with COPD,
but not in cultured bronchial epithelial cells from smokers
with normal pulmonary function [101]. As similar results
were noted for concentrations of the pro-inflammatory
cytokine IL-1b, this suggests that not all smokers are equally
susceptible to cigarette-smoke induced alterations to the pul-
monary inflammatory response.
Vascular diseases
The pathogenesis of atherosclerosis, the precursor to most
acutecoronarysyndromesandstrokes,includestheactivation
of vascular endothelial cells, and the recruitment of
inflammatory cells, predominantly macrophages, to the ves-
sel wall [35, 102, 103]. Leukocyte- endothelial recruitment is
adhesion molecule-dependent, and smoking is a major risk
factor for vascular diseases. Therefore, attention has inevita-
bly turned to examinations of the influence of tobacco smok-
ing on adhesion molecule expression by vascular endothelial
cells. Indeed, tobacco smoking has long been known to in-
duce leukocyte-endothelial adhesion and leukocyte entrap-
ment, as noted earlier.
Monocyte-endothelial interaction is clearly multifactorial.
However, endothelial ICAM-1 expression is likely to exert a
strong influence on such cell-cell adhesions. Adams et al.
[102] were able to show upregulation of ICAM-1 (but not
VCAM-1 or E-selectin) expression on HUVECs exposed to
smokers serum, and to confirm increased monocyte-endothe-
lium adhesion in smokers selected to exhibit no other major
risk factor for vascular disease. Nicotine has been shown to in-
duce an increase in VCAM-1 mRNA synthesis, but not
E-selectin, in primary human coronary artery endothelial
cells, but a 1.6 fold elevation required 24 hr exposure to a con-
centration of nicotine as high as 10
-5M (or 1.6 mgm l
-1), which
is higher than normal physiological exposure levels [17,
104, 105]. Weber et al. [89] determined that increased
monocyte-endothelial adhesion in smokers is CD11b-depend-
ent, through the use of a blocking anti-CD11b antibody. How-
ever, CD11b was not increased on the surface of freshly
isolated monocytes. This indicates that smoking may lead to
increased monocyte-HUVEC adhesion by influencing an en-
dothelial Mac-1 ligand, with ICAM-1 the prime candidate, or
thatsmokingmayinduceconformational,orother,alterations
toMac-1,leadingtoincreasedaffinityforICAM-1.Indeed,in-
creased expression of CD11b may not be required or suffi-
cient for increased leukocyte-endothelial adhesion [89, 106,
107].
Neutrophils contain large granular stores of CD11b that
can be rapidly translocated to the surface on activation [108,
109]. Therefore, tobacco-induced translocation of CD11b
could partly explain enhanced neutrophil adhesion in smok-
ers. Recently, Koether et al. [20] exposed whole blood or neu-
trophils isolated from non-smokers to cigarette smoke
condensate (CSC), and observed a rapid (minutes) 2.5 to 3
fold increase in CD18/ CD11b expression on the neutrophil
surface. Other studies have also shown an increased to-
bacco-induced expression of cell surface b2-integrins by leu-
kocytes in in vitro studies [33, 80, 110]. Thus, up-regulation
of CD11b/CD18 in primed neutrophils, coupled with endothe-
lialICAM-1expression,wouldbeexpectedtocontributetoin-
appropriate neutrophil adhesion in smokers in cardiovascular,
pulmonary, or other environments, with potential ramifica-
tions to local tissue integrity. However, this specific issue is
not clearcut. Most in vivo, and some in vitro, studies in hu-
mans have not shown a difference between expression levels
of b2-integrins on neutrophils and monocytes and of smokers
and non-smokers [4, 7, 105, 111], which hints at a need for
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physiologically relevant dosing in in vitro models. Typical se-
rum nicotine levels in smokers are in the region of 30 ng ml
-1
[17, 104, 105].
Shen et al. started the important task of dissecting the sig-
nalling pathways that underlie tobacco-induced monocyte-en-
dothelial adhesion [33]. Cigarette smoke condensate (CSC)
was shown to induce surface expression of ICAM-1,
VCAM-1, and E-selectin on HUVECs and bovine aorta endo-
thelial cells. Nicotine alone, even at 25 mg ml-1, did not influ-
ence endothelial adhesion molecule profiles. Inhibitors of
proteinsynthesis(cycloheximide),transcription(actinomycin
D) and protein kinase C (GF 109203X and chelerythrine), es-
tablishedthatincreasedendothelialadhesionmoleculeexpres-
sion required de novo adhesion molecule production, via a
PKC-dependentpathway.NF-kB,atranscriptionfactor,binds
to a consensus site in specific adhesion molecule genes. Shen
et al. [33] established the importance of CSC-induced NF-kB
activation in the upregulation of endothelial adhesion mole-
culeexpression.Furthermore,CSCincreasedthemigrationof
monocyticcellsacrossHUVECsandbovineaortaendothelial
cells, concomitant with an up to 10-fold increase in
PECAM-1 phosphorylation, which was inhibited by PKC in-
hibitors. Unfortunately, such studies on the molecular mecha-
nisms by which smoking may dysregulate the expression and
releaseofspecificadhesionmoleculesarerare,andthereisan
obvious need for a concerted research effort in this area.
Several groups have attempted to reduce smoking-in-
duced leukocyte-endothelial adhesion in smokers by pharma-
cological intervention with anti-inflammatory agents.
Smoking-induced monocyte-endothelial adhesion in humans
was acutely abrogated to a significant degree by a single 7g
oral administration of L-arginine, but not vitamin C, suggest-
ing a role for nitric oxide [102]. Weber et al. [89] showed that
ten days of Vitamin C supplementation was successful in re-
ducing monocyte-endothelial adhesion in smokers.
Zapolska-Downar et al. [21] noted that oral administration of
the non-steroidal anti-inflammatory drug ibuprofen reduced
monocyte-HUVEC adhesion in smokers.
Adhesion molecule-mediated platelet aggregation repre-
sents a mechanism contributing to acute coronary events in
smokers [22]. Accordingly, it has been shown that P-selectin
expression is generally increased on the surface of platelets in
smokers, a process that requires translocation of P-selectin
from the intracellular a-granules [22, 112]. In vivo platelet ac-
tivation, and the associated alterations in cell surface presenta-
tion of P-selectin molecules, can occur immediately after
smoking a cigarette [22]. The increased surface of P-selectin
on platelets is not affected by aspirin administration (2 weeks
at 100 mg/day) [112].
Chronic inflammatory periodontal disease:
Chronic inflammatory periodontal disease (CIPD) is a
common disease of the supporting tissues of the teeth, result-
ing from a complex interaction between plaque bacteria and
the host response. Like vascular disease and COPD, tobacco
smoking is also a major risk factor for the development, pro-
gression, and exacerbation of periodontitis [113-116].
ICAM-1 expression is increased in the gingival
vasculature during episodes of experimental gingivitis, -in-
duced on cessation of normal oral hygiene procedures- coinci-
dent with peak measurements of IL-1 in the gingival
crevicularfluid(GCF;aserum-derivedfluidthatexudesfrom
the gingival sulcus) [117]. Rezavandi et al. [18] examined ad-
hesion molecule profiles in periodontal tissues taken from
smokers and non-smokers undergoing surgical treatment for
CIPD. Compared to non-inflamed areas, the proportion of the
microvasculature expressing ICAM-1 and E-selectin was sig-
nificantly increased in inflamed areas of tissues, irrespective
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Figure 2. Expression of ICAM-1 in the gingival tissues of a smoker and
non-smoker with chronic inflammatory periodontal disease.
Typical histological sections of gingival tissue from a smoker (A) and a non-
smoker (B) with CIPD. Tissue sections were labelled with monoclonal anti-
bodies to ICAM-1, visualised with streptavidin-biotin peroxidase complex
developed with diaminobenzidine/hydrogen peroxide, and counter-stained
with haematoxylin. ICAM-1 positive cells (dark staining) are predominantly
endothelial. The percentage of ICAM-1-positive vessels of the gingival
microvasculature was determined following immunostaining of von
Willebrand factor, an endothelial marker, in adjacent sections.of smoking status. However, although smokers had thus re-
tained the ability to upregulate adhesion molecule expression,
an integral part of the inflammatory response, other signs of
smoking-induced immune dysregulation in the gingival
microvasculature were apparent. There was no statistically
significantdifferenceinthenumberofsmallbloodvessels,de-
tected by immunostaining of von Willebrand factor, in in-
flamed and non-inflamed areas of the gingival tissues of
smokers. In other words, the normal angiogenic response that
helps to define inflammation was compromised.
Rezavandi et al. [18] also noted that in histologically nor-
mal, non-inflamed periodontal tissues, the percentage of ves-
sels expressing ICAM-1 was reduced in smokers. Thus, basal
endothelial ICAM-1 expression levels may be compromised.
Typical expression profiles of ICAM-1 in the gingival tissues
of a smoker and non-smoker with CIPD are presented in Fig-
ure 2. As mentioned earlier, constituents of tobacco smoke
can induce ICAM-1 expression on endothelial cells [33, 80,
93, 102]. One possible outcome of long-term tobacco smoke
exposure is tolerance, with respect to ICAM-1 expression. It
is also a possibility that the reduced level of ICAM-1 expres-
sioninnormalgingivaltissuescouldreflectongoingshedding
ofmembrane-boundICAM-1.Smokersare,indeed,knownto
carry a high load of a soluble form(s) of ICAM-1 in the sys-
temic circulation [105, 118], a topic we shall re-address
shortly.
In contrast to the pulmonary alveolar space, the absolute
number of neutrophils in the GCF or oral cavity fluids of
smokers is comparable or lower in smokers, compared to
non-smokers [119, 120]. This is despite the increased number
of neutrophils in the systemic circulation of smokers [5, 7].
The reduced angiogenic response and compromised endothe-
lial ICAM-1 expression profiles in the gingival tissues of
smokers may help explain this initially surprising
observation.
In summary, there is growing evidence that smoking influ-
ences tissue and cellular adhesion molecule expression pro-
files in several smoking-induced diseases: COPD; vascular
diseases; and CIPD. However, such studies are at a prelimi-
nary stage, all tissues do not appear to respond equally, and
theinvivoevidenceforsmoking-inducedcell-associatedadhe-
sion molecule dysregulation has been obtained primarily with
small numbers of patients. Further research into the influence
of tobacco on adhesion molecules in smoking-induced inflam-
matory disease is warranted and necessary.
SOLUBLE ADHESION MOLECULES
Soluble forms of many adhesion molecules are recognised
(see Figure 3), but the relevance of these circulating forms of
adhesion molecules is not clearly understood. Specific circu-
lating adhesion molecules are proteolytically released from
the cell surface of activated immune cells [45, 48, 121], there-
fore, these circulating adhesion molecules may simply reflect
general immune function. However, there is convincing
evidence that certain soluble adhesion molecules remain
bioactive and have the potential to interfere with a variety of
immunologic / inflammatory processes [29, 122]. As noted
early on by Gearing and Newman [29], there are two obvious
means by which soluble forms of adhesion molecules may
have significant physiological influence - (i) by competitive
inhibitionofcell-cellinteractionsand,(ii)bybindingtotheap-
propriate ligand on the surface of a cell, thereby eliciting a
response.
sICAM-1
The evidence that tobacco smoking leads to a significant
increaseincirculatinglevelsofsICAM-1isoverwhelming.In
an investigation into the relationship between local
(periodontal) and systemic inflammation, a significant eleva-
tion of sICAM-1 in smoking subjects, independent of
periodontal status, was noted [118]. This observation has
since been confirmed by many authors [105,123-135]. In the
pulmonary environment, involuntary cigarette smoke expo-
sure (environmental or passive smoking) has been associ-
ated with significantly increased ICAM-1 concentrations in
thebronchoalveolarlavagefluidofchildren[136].Rumallaet
al. [137] noticed a 10 fold elevation in sICAM-1 levels in the
pulmonary lavage fluids of some individual smokers.
Cigarette smoking does not seem to lead to an acute in-
crease in circulating sICAM-1 levels [105, 125]. Thus, raised
circulating sICAM-1 levels in smokers could reflect to-
bacco-induced vascular damage, or other underlying patholo-
gies. However, further studies have since established that the
influence of smoking on sICAM-1 levels is dose-dependent
and reversible. There is a strong correlation between
sICAM-1 levels and several quantitative indices of recent to-
baccosmoke intake-expired-air COlevels[138]; plasmaand
serum cotinine concentrations [105, 138]; a composite index
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Figure 3. Release of soluble adhesion molecules.oftobaccointake[138];andthesystemicnicotineintakefrom
a single cigarette [105]. Systemic sICAM-1 levels decline rap-
idly on smoking cessation to levels approaching that of
non-smokers [125, 138]. Much of this recovery occurs in the
first four weeks following biochemically-validated cessation
(unpublished data). Taken as a whole these data provide
strong evidence that tobacco smoking is a direct causative
agent of a systemically increased sICAM-1 burden. The de-
cline in sICAM-1 levels noted on cessation is not compro-
mised by high-dosage nicotine replacement therapy, in the
form of transdermal nicotine patches (unpublished data).
Therefore,itisacomponent(ormetabolite)oftobaccosmoke
other than nicotine (or cotinine) that is responsible for ele-
vated sICAM-1 concentrations in smokers. Typical concentra-
tions of circulating adhesion molecules are presented in
Table 1.
sICAM-1 and disease
A growing number of studies report a significant associa-
tion between elevated sICAM-1 levels, and the presence of
most vascular diseases; the prediction of future adverse
events; and poor prognosis [128, 131, 134, 142-149]. Thus,
elevated sICAM-1 levels may have serious consequences. Se-
rum sICAM-1 concentrations are also reported to be signifi-
cantly elevated in subjects with other diverse disease entities,
including non-small-cell lung cancer and other malignancies
[127, 150], diabetes [29, 151], cystic fibrosis [152], inflamma-
tory bowel diseases [153], bronchial asthma [154], allergic
alveolitis [155, 156], and several other inflammatory dis-
eases. However, a majority of such studies have not consid-
ered smoking habits. Therefore some degree of re-evaluation
of sICAM-1 as a disease marker may be required in light of
the profound, and reversible, influence of tobacco smoke on
sICAM-1.
Blannetal.[157]reportedthatincreasedsICAM-1concen-
tration was only a weak predictor of disease progression in pe-
ripheral atherosclerosis, when the study population was
balanced for age, gender, and smoking status. Wallen et al.
[134] observed that while elevated sICAM-1 levels in those
with angina pectoris was associated with cardiovascular
death, or non-fatal myocardial infarction (354 ng ml
-1,n=7 )
compared to those who remained event free (282 ng ml
-1,
n = 86), clinical risk factors, including smoking (57% vs
21%), were more prevalent in those with a poor outcome. Ad-
ditionally, mean sICAM-1 was significantly raised in smok-
ers, compared to never-smokers, to a comparable extent to
that noted between coronary event and event free groups. Sim-
ilarly, OMalley et al. [130] observed a significant increase in
sICAM-1 levels in a group of individuals with ischaemic
heartdisease,bothattimeofpresentationwithchestpain,and
three months later, compared to healthy controls. Therefore,
sICAM-1 levels where not influenced by the acute event.
However, for the purposes of this review it is most interesting
that sICAM-1 elevation was confounded by cigarette smok-
ing. Fassbender et al. [126] monitored soluble adhesion mole-
cule profiles in 173 subjects with cerebrovascular disaeases,
and 67 controls. Although, there was an increase in sICAM-1
levels in the total population with cerebrovascular disease
compared to controls (275 ng ml
-1 vs 260 ng ml
-1, respec-
tively),thediseasedpopulationcontainedtwicethenumberof
smokers, and the authors note that sICAM-1 levels were sig-
nificantly increased in smoking subjects. Again, Rifai et al.
[158] examined sICAM-1 levels in the plasma of 100 men
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Table 1. Typical systemic adhesion molecule concentrations (ng ml
-1) in age and gender matched smokers, non-smokers, and ex-smokers
Adhesion molecule Non-smokers Smokers Ex-smokers**
sP-selectin 70 - 150 60 - 145 -
sL-selectin 760 - 1200 940 - 1100 -
sE-selectin 40 - 45 40 - 45 -
sICAM-1 220 - 300 320 - 380 240 (-71)
sVCAM-1 500 - 610 500 - 595 -
sPECAM-1 25 30 -
sCD44v5 35 60 40 (-13)
sCD44v6 140 265 170 (-62)
* p < 0.05.
** Ex-smokers taken from the pan-European CEASE trial [139]. Ex-smokers smoked ³15 cigarettes per day at baseline (plasma cotinine ³50ng ml
-1); and
ceased tobacco use for 52 weeks. Tobacco cessation was validated biochemically (expired-air CO < 10 ppm and plasma cotinine <15 ng ml
-1) at regular inter-
vals. Ex-smokers were matched for baseline tobacco consumption, gender and age with continuing smokers. Drop in adhesion molecule concentration
(ng ml
-1) over one year given in brackets.
Data taken from [105, 118, 123, 124, 127, 134, 138-141].with angiographically documented coronary heart disease,
and 100 healthy controls matched for age and smoking status.
Under this experimental strategy, there was no significant dif-
ference in median sICAM-1 concentrations between the dis-
eased (335 ng ml
-1) and healthy groups (339 ng ml
-1).
Some studies certainly suggest that elevated sICAM-1 is a
suitable marker of vascular disease status and a risk factor for
futureacutevascularevents[131,146,149],andthatthesesig-
nificant associations are not confounded by smoking habits.
Nevertheless, it has been clearly established that a dramatic,
dose-dependent increase in circulating sICAM-1 levels is one
consequence of tobacco smoking. Therefore smokers will be
more likely to be in the upper quartile of sICAM-1 levels,
where increased risk of vascular disease is most evident [146].
Indeed, the influence of smoking on sICAM-1 concentration
iscommonlyreportedtobeasgreat,orgreater[118,126,158]
as that ascribed to disease [126, 130, 158].
Recently,Beckeretal.(149)havesuggestedthatthesignif-
icant relationship between elevated systemic sICAM-1 and
vascular disease is independent of renal function and major
risk factors such as clinical or sub-clinical atherosclerosis
(prior vascular disease or ankle-brachial pressure index), en-
dothelial activation (von Willebrand factor), inflammation
(C-reactive protein), or elevated sVCAM-1. Thus a causative
link between sICAM-1 and vascular disease has yet to be
firmlyestablished.Whileitislikelythatunderlyinginflamma-
tory disease(s) will contribute to some extent to the systemic
sICAM-1 load, the possibility that the tobacco-induced
sICAM-1 burden may directly influence the immune
response, and thus represent a common factor in tobacco-in-
duced diseases, is deserving of attention. To this end, the
immunomodulatory effects attributed to sICAM-1 that may
be relevant to various disease processes are summarised in
Figure 4. Briefly, stimulation of proteloytic enzyme release
from granulocytes, which has been proposed as a mediator of
multiple organ failure [159], could make a major contribution
to tissue breakdown; stimulation of inflammatory mediator re-
lease may be expected to potentiate the inflammatory re-
sponse; competitive inhibition of leukocyte-endothelial
interactionsmaybeexpectedtocompromisemigrationofacti-
vated leukocytes; inhibition of immune surveillance could
abet tumor cells in evading detection; and promotion of
angiogenesis may aid tumor growth, and have obvious rele-
vance to other angiogenesis-dependent diseases. Detailed ex-
planations of these proposed bioactive sICAM-1 properties
can be obtained from the references provided in the figure leg-
end [47, 159-177].
The antioxidant capacity of smokers is compromised
[178]. The influence of antioxidant therapy on smoking-in-
duced endothelial-leukocyte interactions was discussed
briefly earlier. We are currently in the final stages of a study
examining the short-term influence of high-dose vitamin C
oncirculatingICAM-1levels.However,sinceembarkingon
this study an independent research group [133] has reported
that the elevation of serum sICAM-1 in smokers is not abro-
gatedbylong-termtreatmentwithadifferentclassofantioxi-
dant molecule- a-tocopherol (2 years at 400 IU dL/day).
sICAM-1 levels were reduced in healthy men by
glucocorticoid (dexamethasone) treatment [179].
Molecular characteristics of sICAM-1
sICAM-1 exists as a 80-105kDa monomeric protein [50,
51, 180, 181], and as an unconfirmed immunoreactively dis-
tinct, and essentially uncharacterised, 130kDa protein [182].
Evidence for alternate splicing resulting in two mRNA spe-
cies directly encoding either sICAM-1 or membrane-bound
ICAM-1 in humans has been presented [183]. However, the
majority of studies have found no evidence for alternate
mRNA species in humans, and the predominant theory is that
sICAM-1 is released from the cell surface following proteoly-
sis of the cell-bound form, at a defined site [45, 48, 49, 184].
Dimeric ICAM-1 exhibits significantly higher affinity for its
major ligand (LFA-1) than monomeric ICAM-1 [185, 186].
Young et al. [187] purified sICAM-1 from normal human
serum and the urine of patients with bladder cancer by im-
munoaffinity chromatography and detected only monomeric
sICAM-1, which could not block LFA-1/ICAM-1-dependent
cell-mediated cytolosis of bladder tumour target cells. How-
ever,othershavedescribedsICAM-1dimersandmultimersin
vivo [180,181]. Transcriptional regulation of ICAM-1 is par-
ticularly complex, with unusual post-transcriptional control
mechanisms described [50, 51, 66]. Cell-specific regulatory
mechanisms and cell-specific post-translational modifica-
tions of ICAM-1 proteins may affect ICAM-1 function [184,
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Figure 4. Immunomodulatory functions of sICAM-1.
The following references were considered in the construction of this
illustration.
A.[159-161]. B.[162-165]. C.[47,107,166-170]. D.[171-176]. E.[177].188, 189]. However, to the best of our knowledge, the charac-
ter,andsource,ofICAM-1moleculeselevatedinsmokershas
not yet been investigated. Clearly, clarification of the specific
molecularcharacteristicsofsICAM-1insmokerswouldrepre-
sent a huge step towards an understanding the potential role
of sICAM-1 in smoking-induced diseases. Equally, there is
a pressing need to understand the mechanisms by which com-
ponents, or metabolites, of tobacco smoke induce the
upregulationandsheddingofsICAM-1moleculesfromtheen-
dothelium, and other cellular sources. Interestingly, despite el-
evated systemic sICAM-1 concentration noted in smokers,
there is a consistent decrease, approaching four fold, in GCF
ICAM-1levelsinsmokerswithCIPD[190].Nodifferencebe-
tween serum and GCF sICAM-1 concentration is apparent in
non-smokers. Thus, ICAM-1 molecules are inhibited in their
passage from the periodontal microvasculature or through the
periodontaltissues.ThisindirectlyimpliesthesICAM-1mole-
cules in smokers are active, and may be interacting with to be
determined ligands. However, a reduced angiogenic response
in smokers is another possible explanation for these
observations.
sCD44
In an investigation designed to examine the potential
of specific reputed tumour-associated circulating sCD44
isoforms to act as biomarkers in certain malignancies, Kittl
et al. [140] observed a significant elevation in the mean con-
centration of sCD44 containing the product of exon 5
(sCD44v5) and sCD44 containing the product of exon 6
(sCD44v6), in self-reported smokers, compared to self-re-
ported non-smokers. Total sCD44 has since been shown to be
elevated in the blood of smokers, compared to non-smokers
[191],toasmall,butsignificant,extent.LikesICAM-1,theel-
evations in CD44v5 and v6, but not total CD44, are dose-de-
pendent and reversible [141]. Smoking cessation led to a
reduction in concentrations of both sCD44v5 and sCD44v6
(-13 ng ml
-1 and -62 ng ml
-1, repectively) to levels approach-
ing those reported in non-smokers [140, 141]. Additionally,
sCD44 recovery was not influenced by transdermal nicotine
replacement therapy (unpublished results).
Alterations to circulating sCD44 profiles patterns have
been extensively attributed diagnostic and prognostic poten-
tial in several malignancies, including, but not limited to,
non-Hodgkins lymphoma, breast, gastric, and colon cancer
[61, 72, 192-199]. Soluble CD44 is also known to be raised in
subjects with particular inflammatory conditions [200-202].
However, the majority of studies that have examined the po-
tential utility of sCD44 isoforms as disease biomarkers have
not considered smoking status. In light of the recent evidence
thatsmokingexertsaprofounddose-dependentandreversible
influence on systemic concentrations of specific sCD44 vari-
ant molecules, then it may be necessary to re-evaluate as-
cribed diagnostic and prognostic specificities in certain
inflammatory and malignant diseases. Cellular and tissue
CD44 isoform expression patterns have also been widely pro-
posed as markers of tumor growth, metastatic potential, and
poorprognosisinseveralmalignancies,includinglungcancer
[53, 60, 203-210]. Alternations to CD44 profiles have also
been noted in non-cancerous, but pre-neoplastic, lung tissues
[210]. There is, however, evidence that tobacco can induce al-
terations to cell-bound CD44 profiles in normal cells. Nico-
tine and its primary metabolite - cotinine - have both been
shown to alter CD44 expression profiles on lung
microvascular endothelial cells (LEISVO), and bone mar-
row-derived (STR-12) endothelial cells [211]. Therefore, it
may be useful to address the influence of tobacco on the ex-
pressionofmembrane-boundCD44isoformsinsituinadefin-
itive manner in future studies.
Soluble CD44 was first reported in serum over twenty
years ago [212]. Despite this, the physiological relevance of
sCD44 molecules is unclear. However, by analogy with
sICAM-1, it is entirely possible that circulating CD44 mole-
culescouldbeimmunomodulatory.Thereissomeevidenceto
support this theory. In an in vitro system, sCD44 (in
liposomes) was able to partially suppress T cell activation
[213]. Recently, a novel sCD44 splice variant (CD44RC) was
cloned that dramatically enhanced the hyaluronan binding ac-
tivity of cell surface CD44 [214]. This unusual and unex-
pected observation has been suggested to result from
CD44RC binding to chondroitin sulfate side-chains attached
to cell surface CD44. Therefore, a multivalent complex with
increased avidity for hyaluronan is generated. In addition to
this functional originality, CD44RC is produced in a, so far,
uniquemannersplicingofthe3endofCD44exon2intoan
internal site within exon 18, resulting in an altered reading
frame and, thus, a novel CD44 isoform. Other studies have
suggested that sCD44 variants can bind hyaluronate, and that
the affinity of binding is determined by specific
glycosylations [196, 215]. Specific sCD44 molecules can
bind fibronectin [196]. sCD44, in serum, has also been shown
toinhibithumanperipheralbloodlymphocytebindingtoendo-
thelial cells in frozen tonsil sections [196]. Thus, specific
sCD44 molecules are bioactive and, potentially,
immunomodulatory.
Metastasis to the lung following intravenous delivery of
TA3/St murine mammary carcinoma cells is prevented when
the carcinoma cells are transfected with sCD44-encoding
cDNA, where sCD44 probably acts as a competitive inhibitor
of cell surface CD44-hyaluronate interactions [216]. Indeed,
sCD44 transfection was subsequently shown to prevent
hyaluronate-mediated clustering of CD44 on tumour cell sur-
face[60]. Peterson etal.[217] inhibited murine mammary car-
cinomacellgrowththroughtransfectionwithcDNAencoding
hyaluronate-binding sCD44v8-v10 or sCD44v6-v10. Other
studies have also indicated that sCD44 may interfere with the
growth and metastasis of specific tumour cells in mice
[217-220]. Suppression of tumour formation by a human
sCD44 fusion protein has again been demonstrated lately
[221], and a soluble CD44-immunoglobulin fusion protein
was able to block the migration of a CD44H-transfected hu-
man melanoma cell line across a hyaluronate-coated surface
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chor for MMP-9, a matrix metalloproteinase, which may con-
tribute to collagen degradation and contribute to tumor
invasiveness [60]. sCD44 can disrupt CD44/MMP-9 clusters
and inhibit tumor metastasis in vivo [60].
AlternatesplicingoftheCD44pre-mRNApermitsthesub-
sequenttranslationofaplethoraofpotentialCD44variantpro-
teins, whose function may be further modified by extensive
and varied post-translational modifications. The molecular
characteristicsofsmoking-influencedCD44proteinshaveyet
to be ascertained. CD44 has proposed roles in leukocyte-endo-
thelial interactions, there is increasing evidence of several po-
tential mechanisms by which CD44 may play an aetiological
role in certain cancers and vascular diseases [35, 53, 55, 59,
60], there are reputed diagnostic associations between CD44
profiles and various diseases, and there are undoubted connec-
tions between tobacco use and specific cancers and certain
life-threateninginflammatoryprocesses.Considerationofthe
availabledatashowsthatthereisaneedtofurtherdevelopour
understanding of the influence of tobacco smoking on the
CD44gene,andencodedvariantCD44proteinfamily,bothas
a means of properly attributing any diagnostic and prognostic
significance to CD44 molecules, and perhaps, in order to un-
ravel any mechanisms of tobacco-induced disease that may
be, partially at least, CD44-mediated.
Other soluble adhesion molecules
Blann et al. [157] reported that, compared to appropriate
control groups, sVCAM-1 is significantly elevated in the se-
rumofsmokerswithperipheralarterydisease,butnothealthy
smokers, implying an indirect relationship. Elsewhere, much
of the available evidence suggests that tobacco smoking does
not influence sVCAM-1 concentrations [134, 142, 223].
Osterud et al. [224] found that sVCAM-1 levels were actually
lower in male smokers, compared to non-smokers, but this
was not true for females, or combined genders. Equally, and
on balance, smoking does not appear to influence systemic
concentrations of the selectins [105, 112, 118, 151, 225-227],
or PECAM-1 [105, 224, 228]. However, there is some evi-
dence to suggest that smoking could influence sP-selectin lev-
els. Blann et al. [229] observed a significant rise sP-selectin
levels in smokers. However, the smokers and non-smoking
subjects were not matched for age or disease status (deep ve-
nousthrombosis),andthedifferencewasnotimpressive.This
is broadly in agreement with previous reports by the same au-
thors, who have acknowledged that any potential relationship
between smoking and sP-selectin is weak [124, 230-232].
Osterud et al. [224] found a small, but significant, rise in
sP-selectin in the serum of women smokers, compared to
non-smokers, that was not apparent in the male or in the total
study population. Limited evidence suggests that smoking
could influence circulating sE-selectin concentrations.
Kitamura et al. [233] observed a significant increase in serum
sE-selectin levels in heavy smokers (20-40 cigarettes day
-1;
92 ng ml
-1), compared to non-smokers (67 ng ml
-1). However,
this observation was made in subjects with pustulosis
palmaris et plantaris, a dermatological disease that seems to
exert a strong influence on sE-selectin in serum, and it is not
clearhowtheincidenceofthisconfoundingconditionwasdis-
tributed between the smoking and non-smoking groups. Thus,
the balance of evidence suggests that if circulating profiles of
other major adhesion molecules are indeed influenced by to-
bacco smoking, then this influence is certainly not as pro-
found as the dramatic effects seen in sICAM-1 and some
sCD44 variants.
CONCLUDING REMARKS
Research into the relationship between tobacco use and ad-
hesion molecule networks is at an early stage. Smoking di-
rectly causes an increase in soluble ICAM-1 and specific
CD44 variant concentrations in the systemic circulation, dilut-
ing several previous diagnostic and prognostic attributions.
Both sICAM-1 and CD44 are considered to possess several
immunomodulatory properties. Clarification of the specific
sources and molecular characteristics of smoking-influenced
sICAM-1 and sCD44 protein should provide insight into po-
tential functions of soluble adhesion molecules in tobacco-in-
duced diseases. The influence of tobacco on the cellular and
tissue distribution of cell-bound adhesion molecules is less
clear. Smoking status should certainly be considered in stud-
ies that examine potential prognostic and diagnostic assigna-
tions of significance to circulating adhesion molecule profiles
and membrane-bound expression in cells and tissues. This
does not occur in the majority of studies, even in diseases
were the aetiological significance of smoking is unequivocal,
such as neoplastic and malignant lung tissues and COPD. Al-
though there is extensive, and growing, knowledge of the mo-
lecular mechanisms that regulate transcription, expression,
and shedding of ICAM-1, CD44, and other adhesion mole-
cules, studies that address how tobacco smoke may influence
thesecontrolnetworksareminimal.Adhesionmoleculesfunc-
tion at the heart of the immune and inflammatory response.
Dysregulationofthesecriticalmoleculesmayrepresentacom-
mon mechanism(s) underlying susceptibility to a variety
smoking-induced diseases.
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